A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

ClinicalTrials.gov ID: NCT01283971

Public ClinicalTrials.gov record NCT01283971. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid arthritis. Patients, already treated with MTX at stable doses, will be randomized to receive either RoActemra/Actemra 8 mg/kg intravenously (IV) every 4 weeks or adalimumab 40 mg subcutaneous (SC) every 2 weeks. All patients will receive methotrexate (10-25 mg weekly) and folate (at least 5 mg weekly). The anticipated time on study treatment is 24 weeks.

Study identification

NCT ID: NCT01283971
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 4
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 96 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2011
Primary completion: Jul 31, 2012
Completion: Jul 31, 2012
Last update posted: Feb 9, 2014

2011 – 2012

United States locations

U.S. sites: 107
U.S. states: 32
U.S. cities: 98

Facility	City	State	ZIP	Site status
Not listed	Huntsville	Alabama	35801	—
Not listed	Phoenix	Arizona	85027	—
Not listed	Tucson	Arizona	85712	—
Not listed	Covina	California	91723	—
Not listed	Escondido	California	92025	—
Not listed	Huntington Beach	California	92646	—
Not listed	La Mesa	California	91942	—
Not listed	Lakewood	California	90712	—
Not listed	Long Beach	California	90806	—
Not listed	Los Angeles	California	90048	—
Not listed	Sacramento	California	95816-5119	—
Not listed	San Diego	California	92108	—
Not listed	Westlake Village	California	91361	—
Not listed	Whittier	California	90603	—
Not listed	Whittier	California	90606	—
Not listed	Bridgeport	Connecticut	06606	—
Not listed	Hamden	Connecticut	06518	—
Not listed	Norwich	Connecticut	06360	—
Not listed	Newark	Delaware	19713	—
Not listed	Aventura	Florida	33180	—
Not listed	Fort Lauderdale	Florida	33334	—
Not listed	Jupiter	Florida	33458	—
Not listed	Melbourne	Florida	32901	—
Not listed	Naples	Florida	34102	—
Not listed	Ocala	Florida	34474	—
Not listed	Orlando	Florida	32806	—
Not listed	Ormond Beach	Florida	32174	—
Not listed	Palm Habor	Florida	34684	—
Not listed	Palm Harbor	Florida	34684	—
Not listed	Sarasota	Florida	34239	—
Not listed	Tamarac	Florida	33321	—
Not listed	Tampa	Florida	33609	—
Not listed	Atlanta	Georgia	30342	—
Not listed	Valdosta	Georgia	31602	—
Not listed	Idaho Falls	Idaho	83404	—
Not listed	Chicago	Illinois	60611	—
Not listed	Maywood	Illinois	60153	—
Not listed	Moline	Illinois	61265	—
Not listed	Springfield	Illinois	62704	—
Not listed	Fort Wayne	Indiana	46804	—
Not listed	South Bend	Indiana	46601	—
Not listed	Lexington	Kentucky	40515	—
Not listed	Baton Rouge	Louisiana	70808	—
Not listed	Monroe	Louisiana	71203	—
Not listed	Annapolis	Maryland	21401	—
Not listed	Cumberland	Maryland	21502	—
Not listed	Frederick	Maryland	21702	—
Not listed	Hagerstown	Maryland	21740	—
Not listed	Fall River	Massachusetts	02720	—
Not listed	Worcester	Massachusetts	01610	—
Not listed	Battle Creek	Michigan	49015	—
Not listed	Lansing	Michigan	48910	—
Not listed	Petoskey	Michigan	49770	—
Not listed	Saint Claire Shores	Michigan	48081	—
Not listed	Biloxi	Mississippi	39531	—
Not listed	Flowood	Mississippi	39232	—
Not listed	Tupelo	Mississippi	38802	—
Not listed	Springfield	Missouri	65807	—
Not listed	St Louis	Missouri	63117	—
Not listed	Reno	Nevada	89502	—
Not listed	Clifton	New Jersey	07012	—
Not listed	Manalapan	New Jersey	07726	—
Not listed	New Brunswick	New Jersey	08903	—
Not listed	Brooklyn	New York	11201	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10029-6574	—
Not listed	Syracuse	New York	13210	—
Not listed	Charlotte	North Carolina	28204	—
Not listed	Charlotte	North Carolina	28210	—
Not listed	Greensboro	North Carolina	27408	—
Not listed	Greenville	North Carolina	27834	—
Not listed	Raleigh	North Carolina	27617	—
Not listed	Washington	North Carolina	27889	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Middleburg Heights	Ohio	44130	—
Not listed	Toledo	Ohio	43606	—
Not listed	Oklahoma City	Oklahoma	73109	—
Not listed	Lake Oswego	Oregon	97035	—
Not listed	Duncansville	Pennsylvania	16635	—
Not listed	Philadelphia	Pennsylvania	19152	—
Not listed	Pittsburgh	Pennsylvania	15237	—
Not listed	Pittsburgh	Pennsylvania	15261	—
Not listed	Willow Grove	Pennsylvania	19090	—
Not listed	Wynnewood	Pennsylvania	19096	—
Not listed	Wyomissing	Pennsylvania	19610	—
Not listed	Charleston	South Carolina	29406	—
Not listed	Myrtle Beach	South Carolina	29572	—
Not listed	Jackson	Tennessee	38305	—
Not listed	Memphis	Tennessee	38104	—
Not listed	Memphis	Tennessee	38119	—
Not listed	Austin	Texas	78731	—
Not listed	Carrollton	Texas	75007	—
Not listed	Corpus Christi	Texas	78404	—
Not listed	Houston	Texas	77004	—
Not listed	Houston	Texas	77034	—
Not listed	Houston	Texas	77070	—
Not listed	Houston	Texas	77074	—
Not listed	Mesquite	Texas	75150	—
Not listed	San Antonio	Texas	78217	—
Not listed	San Antonio	Texas	78258	—
Not listed	Sugar Land	Texas	77479	—
Not listed	Arlington	Virginia	22205	—
Not listed	Kennewick	Washington	99336	—
Not listed	Spokane	Washington	99204	—
Not listed	Tacoma	Washington	98405	—
Not listed	Clarksburg	West Virginia	26301	—
Not listed	Franklin	Wisconsin	53132	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01283971, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 9, 2014 · Synced Sep 24, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01283971 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →